• Birinapant is a second generation bivalent SMAC mimetic in development for cancer and Hepatitis B.
  • SHAPE SHAPE is a novel HDAC inhibitor being developed for topical use in early-stage CTCL.

Active Clinical Programs

Oncology Phase 1 Phase 2 Phase 3
Myelodysplastic Syndromes (MDS) Birinapant
Cutaneous T-Cell Lymphoma (CTCL) SHAPE
Ovarian Cancer Birinapant
Infectious Disease
Hepatitis B Birinapant